Aarti Drugs Limited (NSE:AARTIDRUGS)
India · Delayed Price · Currency is INR | Market Cap | 45.17B +0.8% |
| Revenue (ttm) | 28.51B +15.1% |
| Net Income | 2.29B +14.9% |
| EPS | 25.06 +9.5% |
| Shares Out | n/a |
| PE Ratio | 19.73 |
| Forward PE | 20.19 |
| Dividend | 2.00 (0.40%) |
| Ex-Dividend Date | Feb 9, 2026 |
| Volume | 1,877,757 |
| Open | 497.20 |
| Previous Close | 499.75 |
| Day's Range | 490.00 - 507.65 |
| 52-Week Range | 318.95 - 522.75 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Aarti Drugs
Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidaz... [Read more]
Financial Performance
In fiscal year 2026, Aarti Drugs's revenue was 25.65 billion, an increase of 7.47% compared to the previous year's 23.87 billion. Earnings were 1.95 billion, an increase of 15.91%.
Financial StatementsNews
Aarti Drugs Transcript: Q2 26/27
Q2 revenue rose 27% YoY to INR 829 crore, with record EBITDA of INR 138 crore and PAT of INR 83 crore. Management expects steady-state margins slightly above 15%, while capacity expansion and formulation exports support growth.
Aarti Drugs Quarterly report: Q2 2027
Aarti Drugs has published its Q2 2027 quarterly earnings report on November 4, 2026.
Aarti Drugs Slides: Q2 2027
Aarti Drugs has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 4, 2026.
Aarti Drugs Slides: FY 2026
Aarti Drugs has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 26, 2026.
Aarti Drugs Transcript: Q1 26/27
Q1 FY 2027 delivered strong revenue and margin growth, driven by higher API realizations, robust specialty chemical performance, and operational resilience amid global volatility. Capacity expansions and regulatory approvals position the business for 10%-15% volume growth and margin improvement.
Aarti Drugs Quarterly report: Q1 2027
Aarti Drugs has published its Q1 2027 quarterly earnings report on August 3, 2026.
Aarti Drugs Slides: Q1 2027
Aarti Drugs has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 3, 2026.
Pharma sector stocks today, July 7: Aarti Drugs jumps 1.84%, Zydus Life rises 1.16%, Divis Lab up 1.18%
Indian pharmaceutical stocks showed a mixed trend in early trade on July 7, with gains in some counters offset by losses in others. Here is a complete snapshot of pharma…
Pharma sector stocks today, May 26: Wockhardt rises 3.91%, Sudeep Pharma up 2.10%, Aarti Drugs gains 2.35%
Pharmaceutical stocks showed a mixed performance on May 26, 2026, during the morning session. While several stocks posted gains, a few names traded lower. The BSE Healthcare index was down…
Pharma sector stocks today, May 19: Strides Pharma crashes 4.84%, J.B. Chemicals rises 2.09%, Aarti Drugs up 2.90%
Pharmaceutical stocks showed a mixed trend on May 19, 2026, during the morning trading session. While several companies posted decent gains, a few stocks faced sharp selling pressure. The BSE…
Pharma Stocks Today, May 19: Strides Pharma crashes 4.84%, J.B. Chemicals rises 2.09%, Aarti Drugs up 2.90%
**Indian Pharma Stocks Today, May 19: Strides Pharma crashes 4.84%, J.B. Chemicals rises 2.09%, Aarti Drugs up 2.90%**Indian pharmaceutical stocks showed a mixed trend on May 19 2026 during the…
Aarti Drugs Transcript: Q4 25/26
Q4 FY 2026 saw strong sequential recovery with revenue up 20% QoQ and EBITDA margin at 13.4%. Backward integration and new facility ramp-ups are expected to drive margin improvement, while export and regulated market contributions continue to rise.
Aarti Drugs Quarterly report: Q4 2026
Aarti Drugs has published its Q4 2026 quarterly earnings report on May 18, 2026.
Aarti Drugs Slides: Q4 2026
Aarti Drugs has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 18, 2026.
Aarti Drugs Annual report: Q4 2026
Aarti Drugs has published its Q4 2026 annual report on May 18, 2026.
Pharma sector stocks fall today, May 18: Alembic Pharma crashes 8.32%, Natco Pharma down 2.48%, Aarti Drugs declines 2.27%
Indian pharmaceutical stocks traded mostly lower on May 18 2026 during the morning session. The BSE Healthcare index declined 0.87% to 46,781.22, in line with the broader market weakness. The…
Aarti Drugs reports Rs 721.1 crore revenue in Q4 FY26 with 6% YoY growth
Aarti Drugs Limited, a diversified pharmaceutical company based in Mumbai, announced its audited financial results for the fourth quarter and financial year ending 31st March 2026. The company reporte...
Aarti Drugs reports comprehensive income of ₹17,169 crore for FY26
Aarti Drugs Limited has announced its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026. The company's total comprehensive income for the year stood…
Pharma sector stocks surge today, April 27: Sun Pharma jumps 6.62%, Aarti Drugs up 3.50%, Alembic Pharma rises 2.86%
Indian pharmaceutical stocks broadly advanced on Monday morning, with the Nifty Pharma Index rising 2.4% to 23,131.5. The S&P BSE Healthcare Index climbed 1.47% to 44,259.96, outperforming the broader...
Aarti Drugs launches 'Saksham Niveshak' campaign to address unpaid dividends
Aarti Drugs has announced the relaunch of the 'Saksham Niveshak' campaign, a 100-day initiative aimed at reaching out to shareholders with unpaid or unclaimed dividends. The campaign, which runs from…
Pharma sector stocks today, March 12: Divi's Laboratories down 1.87%, Abbott India drops 1.51%, Aarti Drugs falls 1.36%
The Indian pharmaceutical sector experienced a decline on March 12, 2026, with most listed stocks trading lower in early morning sessions. The S&P BSE HEALTHCARE Index stood at 43,421.7, down…
Aarti Drugs Transcript: Q3 25/26
Revenue and PAT grew strongly YoY, despite margin pressure from weak antibiotic demand and supply chain issues. New facilities and backward integration are ramping up, with significant CapEx planned for oncology and specialty chemicals. Gross margin and EBITDA are expected to improve as utilization increases.
Aarti Drugs Quarterly report: Q3 2026
Aarti Drugs has published its Q3 2026 quarterly earnings report on February 4, 2026.
Aarti Drugs Slides: Q3 2026
Aarti Drugs has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 4, 2026.
Pharma sector stocks today, Feb 4: Suven Life Sciences jumps 9%, Aarti Drugs falls 6%, Shilpa Medicare up 2.80%, Mankind Pharma down 2.92%
The pharma sector displayed mixed performance in early trading on February 4, 2026. While some stocks recorded gains, others faced...